Cyclacel Pharmaceuticals (CYCC) Insider Trading & Ownership $7.99 -0.01 (-0.13%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$8.03 +0.04 (+0.50%) As of 08/22/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Cyclacel Pharmaceuticals (NASDAQ:CYCC) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage51.20%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)2Amount OfInsider Selling(Last 12 Months)$5.92M Get CYCC Insider Trade Alerts Want to know when executives and insiders are buying or selling Cyclacel Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address CYCC Insider Buying and Selling by Quarter Cyclacel Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame Start Date End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails7/30/2025David E LazarMajor ShareholderSell6,750$12.36$83,430.00 2/26/2025David E. LazarCEOSell810,953$7.20$5,838,861.60 (Data available from 1/1/2013 forward) CYCC Insider Trading Activity - Frequently Asked Questions Who is on Cyclacel Pharmaceuticals' Insider Roster? The list of insiders at Cyclacel Pharmaceuticals includes David E Lazar, Paul Mcbarron, and Spiro George Rombotis. Learn more on insiders at CYCC. What percentage of Cyclacel Pharmaceuticals stock is owned by insiders? 51.20% of Cyclacel Pharmaceuticals stock is owned by insiders. Learn more on CYCC's insider holdings. Which Cyclacel Pharmaceuticals insiders have been buying company stock? The following insiders have purchased CYCC shares in the last 24 months: Paul Mcbarron ($5,560.80), and Spiro George Rombotis ($19,860.00). How much insider buying is happening at Cyclacel Pharmaceuticals? Insiders have purchased a total of 32 CYCC shares in the last 24 months for a total of $25,420.80 bought. Which Cyclacel Pharmaceuticals insiders have been selling company stock? The following insider sold CYCC shares in the last 24 months: David E Lazar ($83,430.00). How much insider selling is happening at Cyclacel Pharmaceuticals? Insiders have sold a total of 817,703 Cyclacel Pharmaceuticals shares in the last 24 months for a total of $5,922,291.60 sold. Cyclacel Pharmaceuticals Key ExecutivesMr. Spiro George Rombotis (Age 65)President, CEO & Executive Director Compensation: $612.47kMr. Paul McBarron (Age 63)Executive VP of Finance, CFO, COO, Secretary & Executive Director Compensation: $321.61kDr. Brian Schwartz M.D. (Age 62)Interim Chief Medical Officer & Director Compensation: $53kMs. Gill Christie (Age 67)Director of Human Resources Grace KimInvestor Relations Executive More Insider Trading Tools from MarketBeat Related Companies NRx Pharmaceuticals Insider Trading Lantern Pharma Insider Trading vTv Therapeutics Insider Trading Prelude Therapeutics Insider Trading Coeptis Therapeutics Insider Trading Century Therapeutics Insider Trading Shattuck Labs Insider Trading Aligos Therapeutics Insider Trading Tempest Therapeutics Insider Trading Jasper Therapeutics Insider Trading Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Buy, Sell, or Hold? Insiders Pile Into These 3 Healthcare StocksInsiders Trade Millions in NVIDIA-Linked Navitas, Hims, & Shift45 Stocks Insiders Are Selling That Analysts Say BuyStrategy Insiders Buy In While Analysts Predict Big UpsideThe Bottom Is in For These 3 Small-Cap Stocks Insiders Are Buying This page (NASDAQ:CYCC) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersNations are at war over what’s in this boxA resource known as Element 29 is quickly becoming one of the most sought-after materials on the planet. Goldm...Behind the Markets | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredCover all your expenses with just $118,000 invested?Generate up to $5,000/month with 10X less money? That's what every financial advisor tells you. But I just ...Investors Alley | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredTrump’s “new dollar” could shock Americans"I Made Millions in the Tech Boom. Here's Where I'd Put My Money Today" This man has called some of the big...Stansberry Research | SponsoredHere's the last trade you should make before heading out for the weekend tomorrow.On a quiet Friday afternoon, one trader spotted an overlooked stock. He bought shares. He shut down his ...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cyclacel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cyclacel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.